Vigabatrin - Targeon SAS

Drug Profile

Vigabatrin - Targeon SAS

Alternative Names: Vigabatrin soluble tablet formulation - Targeon SAS

Latest Information Update: 02 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Targeon
  • Class Aminobutyric acids; Antiepileptic drugs; Small molecules
  • Mechanism of Action 4-aminobutyrate transaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Epilepsy; Infantile spasms

Most Recent Events

  • 01 May 2014 Clinical trials in Epilepsy (In children, In infants) in France (PO)
  • 01 May 2014 Clinical trials in Infantile spasms (In children, In infants) in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top